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ABSTRACT
Objective To examine use of CT colonography (CTC) in
the English Bowel Cancer Screening Programme (BCSP)
and investigate detection rates.
Design Retrospective analysis of routinely coded BCSP
data. Guaiac faecal occult blood test (gFOBt)-positive
screenees undergoing CTC from June 2006 to July 2012
as their ﬁrst-line colonic investigation were included.
Abnormalities found at CTC, subsequent polyp, adenoma
and cancer detection and positive predictive value (PPV)
were calculated. Detection rates were compared with
those observed in gFOBt-positive screenees investigated
by colonoscopy. Multilevel logistic regression was used
to examine factors associated with variable detection.
Results 2731 screenees underwent CTC. Colorectal
cancer (CRC) or polyps were suspected in 1027
individuals (37.6%; 95% CI 33.8% to 41.4%); 911 of
these underwent conﬁrmatory testing. 124 screenees
had CRC (4.5%) and 533 had polyps (19.5%), 468
adenomatous (17.1%). Overall detection was 24.1%
(95% CI 21.5% to 26.6%) for CRC or polyps and
21.7% (95% CI 19.2% to 24.1%) for CRC or adenoma.
Advanced neoplasia was detected in 504 screenees
(18.5%; 95% CI 16.1% to 20.8%). PPV for CRC or
polyp was 72.1% (95% CI 66.6% to 77.6%). By
comparison, 9.0% of 72 817 screenees undergoing
colonoscopy had cancer and 50.6% had polyps;
advanced neoplasia was detected in 32.7%. CTC
detection rates and PPV were higher at centres with
experienced radiologists (>1000 examinations) and at
high-volume centres (>175 cases/radiologist/annum).
Centres using three-dimensional interpretation detected
more neoplasia.
Conclusions In the BCSP, detection rates after positive
gFOBt are lower for CTC than colonoscopy, although
populations undergoing the two tests are different.
Centres with more experienced radiologists have higher
detection and accuracy. Rigorous quality assurance of
BCSP radiology is needed.
INTRODUCTION
UK colorectal cancer (CRC) mortality is relatively
poor compared with Europe
1 and the USA.
2
Prognosis is related to stage at diagnosis, with
5-year survival ranging from 94% for cancers con-
ﬁned to the bowel wall to 5% for those with
distant metastases.
3 Detecting early-stage disease in
asymptomatic individuals via screening with guaiac-
based faecal occult blood testing (gFOBt) reduces
disease-speciﬁc mortality by 16% in those offered
screening and 25% in those who accept it.
4 gFOBt
screening is also cost-effective, at £3000 per
quality-adjusted life-year gained.
5 Consequently,
since April 2006, the Department of Health in
England has funded a national programme of bien-
nial gFOBt screening at age 60–69 years (subse-
quently extended to age 70–74; those 75 or over
may ‘opt-in’).
Fifty percent of subjects with a positive gFOBt
result have underlying neoplasia, and a positive
result must be investigated further, usually via col-
onoscopy. However, total colonoscopy is occasion-
ally not possible or is considered too hazardous
Signiﬁcance of this study
What is already known about this subject?
▸ Meta-analysis and randomised trials suggest CT
colonography (CTC) is not signiﬁcantly different
to colonoscopy for detection of colorectal
cancer.
▸ CTC is used in the Bowel Cancer Screening
Programme (BCSP) when colonoscopy is
contraindicated or incomplete.
▸ BCSP endoscopists are rigorously quality
assured: CTC quality assurance is in
development.
What are the new ﬁndings?
▸ In the BCSP, 18.5% of guaiac faecal occult
blood test-positive screenees investigated with
CTC had advanced neoplasia detected,
compared with 32.7% for colonoscopy.
▸ Screenees investigated with CTC and
colonoscopy are fundamentally different
populations and reasons for differences in
detection rates are speculative at this stage.
▸ Centres with radiologists of higher average CTC
experience, greater CTC workload and using
three-dimensional interpretation had
signiﬁcantly higher detection rates.
How might it impact on clinical practice in
the foreseeable future?
▸ Urgent quality assurance, encompassing
technical and interpretive quality, is needed in
the BCSP in case these data are due to
suboptimal CTC practice.
▸ Minimum standards for CTC radiologists should
be applied.
▸ Service reconﬁguration may be necessary to
ensure BCSP CTC examinations are interpreted
by experienced radiologists.
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(CTC) has recently replaced barium enema as the alternative
test recommended by the English Bowel Cancer Screening
Programme (BCSP).
6 This paper describes usage and outcomes
for CTC for the ﬁrst 6 years of the English BCSP .
METHODS
Programme structure
The BCSP has been described previously.
7 In summary, eligible
English residents are sent an invitation letter and information
leaﬂet, and subsequently a gFOBt kit (Hemascreen;
Immunostics, New Jersey, USA) with a prepaid return envelope.
Kits are returned to one of ﬁve screening hub laboratories.
Subjects testing positive are informed by post and invited to
meet a specialist screening practitioner (most often a nurse) at
one of 58 screening centres. The nature of colonoscopy and its
risks and beneﬁts are explained, and a health assessment per-
formed. Consenting screenees undergo colonoscopy, performed
by a screening-accredited practitioner. The Programme was pro-
gressively introduced across England, beginning in July 2006
and completing ‘roll-out’ in 2011.
Although colonoscopy is preferred for screenees testing posi-
tive for gFOBt, CTC may substitute if the subject is unable to
safely complete colonoscopic bowel preparation, is too frail or
immobile to undergo colonoscopy although potentially ﬁt for
necessary treatment, or colonoscopy is deemed otherwise con-
traindicated.
6 CTC is also performed following incomplete col-
onoscopy. Barium enema was used until randomised trial data
made available to the BCSP in 2010 suggested its detection rates
for neoplasia were signiﬁcantly inferior to CTC.
8
Data identiﬁcation
The Bowel Cancer Screening System (BCSS) is the BCSP clinical
database, populated with screenee demographics from the
English National Health Application and Infrastructure Services
systems. As episode results become available, they are manually
entered at the screening centres. We used these routinely coded
data to perform a service evaluation approved by the BCSP
Evaluation Group and the BCSP Radiology Quality Assurance
Group, primarily focusing on CTC abnormality rates, subse-
quent conﬁrmatory testing, detection of cancers and polyps and
adenomas. A waiver to publish anonymised data gathered retro-
spectively was obtained from the Joint Research Ofﬁce of the
Chief Investigator.
We identiﬁed screenees having CTC within the BCSP as the
ﬁrst-line whole-colon investigation following positive gFOBt
between June 2006 and July 2012. We excluded screenees
undergoing completion CTC after incomplete colonoscopy
since many of these will be due to an obstructing tumour (and
hence would inﬂate the CTC cancer detection rate via inclusion
bias). We recorded patient details (age, sex, American Society of
Anesthesiologists (ASA) grade, screening centre attended and
number of times screened previously), abnormalities found at
CTC (suspected polyps and cancers, their diameter and segmen-
tal location), further tests performed after CTC, results from
subsequent endoscopy (including polyp diameter and locations)
and histology for resected polyps and cancers. The same BCSP
database was used to extract polyp and cancer size, morphology
and histology for all colonoscopies performed as the ﬁrst whole-
colon test for evaluation of positive gFOBt in 2011 and 2012.
The largest cancer/polyp diagnosis made in each individual was
recorded, allowing comparison of per-screenee detection rates.
Statistical analysis
Data were analysed using R V .2.15.1.
9 The CTC abnormality
rate was deﬁned as the proportion of screenees undergoing
CTC at which a polyp or cancer was recorded on BCSS.
Abnormality rates were calculated for suspected CRC or large
(10 mm+) polyp, suspected 6–9 mm polyps or suspected
diminutive (≤5 mm) polyps. CRC and 10 mm+ polyps were
grouped together since large polyps were described variably by
different radiologists; that is, as a cancer or large polyp.
Detection rate was deﬁned as the proportion of individuals
undergoing CTC who ultimately had a histologically conﬁrmed
CRC or adenoma matching the CTC abnormality. Matching was
permitted if the CTC and endoscopic sizes were within 50%
and lesions were in the same or adjacent colonic segment.
10
Advanced neoplasia was deﬁned as CRC, adenoma of 10 mm or
greater, a >20% villous component, or high-grade dysplasia.
Positive predictive value (PPV) was deﬁned as the number of
screenees believed to have CRC or a polyp on CTC and in
whom at least one matched lesion was subsequently conﬁrmed,
divided by the total number of screenees undergoing such add-
itional diagnostic testing following abnormal CTC. Analysis was
performed on a per-screenee basis. Sensitivity cannot be calcu-
lated because no reference result is available for all participants,
particularly those testing negative initially; 95% CIs for propor-
tions were calculated from 2000 random bootstrap samples to
account for clustering by centre.
To determine screenee and centre factors associated with
detection, multilevel (random effects) binary logistic regression
was performed, with a matched polyp or cancer as the outcome
variable. screenee-level covariates included screenee age, gender,
screening round for the individual (ie, number of times that
individual had previously been screened) and centre-level cov-
ariates were average radiologist CTC experience, preferred
reading strategy (two-dimensional (2D) or 3D), centre CTC
workload and bowel preparation technique. Screenee-level cov-
ariates were taken directly from the central database, whereas
centre-level covariates were taken from a prior national survey
of CTC practice within the BCSP performed by the authors.
11
Since data were grouped by screening centre, a hierarchical
model incorporated centre as a random effects term using the
package hglm.
12 Funnel plots were used to compare centre var-
iations in CTC abnormality rate, detection rate and PPV . We
identiﬁed centres with a detection rate more than 2 and 3 SDs
(corresponding to calculated 95% and 99.9% control limits)
from the overall average. Plots were drawn in R using ggplot2,
13
according to Spiegelhalter,
14 using exact binomial control limits.
Risk-adjusted detection rates were calculated by analogy with
risk-adjusted mortality used for monitoring surgical perform-
ance.
15 16 The number of observed neoplasms diagnosed by
each centre was divided by the expected number of positives
predicted by the logistic regression model. This observed:
expected ratio was then multiplied by the national average neo-
plasia detection rate to give a risk-adjusted detection rate for
each centre.
RESULTS
Screenee characteristics and overall usage of CTC
From June 2006 to July 2012, 2753 FOBt-positive screenees
were investigated with CTC as their ﬁrst whole-colon test in the
BCSP; 1521 men and 1232 women, spread over three screening
rounds; 22 subjects withdrew prior to investigation, leaving
2731 for subsequent analysis. Screenee demographics are sum-
marised in table 1. The reduction in numbers in each successive
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which did not complete national coverage until 2010.
Median age was 66.5 years (IQR 63.3–69.5 years); males
median 66.4 years (IQR 63.2–69.5 years), females median
66.6 years (IQR 63.3–69.5 years). CTC was used as the initial
colonic investigation following positive gFOBt in only 2.3% of
screenees overall, although this ﬁgure varied substantially across
the 58 centres (0.039%–9.7%, IQR 0.80–3.1%).
CTC ﬁndings, use of conﬁrmatory tests and detection rates
Overall, 1027 individuals were suspected to have CRC or
polyps at CTC, an abnormality rate of 37.6% (95% CI 33.8%
to 41.4%). 462 screenees were diagnosed with CRC or a
10 mm+ polyp at CTC (16.9%), 176 screenees were suspected
to have 6–9 mm polyps (6.4%) and 115 individuals were felt to
have diminutive polyps (4.2%). In 274 screenees (10.0%), the
size and location of the CTC abnormality provoking endoscopy
was absent from the database, although endoscopic size was
available; 427 of the 462 screenees with suspected CRC or
10 mm+ polyp underwent endoscopy or surgery (92.4%), 371
of whom were found to have at least one matched abnormality
(PPV=86.9%; 95% CI 82.7% to 90.9%). A smaller proportion
of those with suspected 6–9 mm and ≤5 mm polyps underwent
conﬁrmatory tests, with PPV also declining as lesion size
reduced (table 2). Ultimately, of the 1027 screenees with a sus-
pected CRC or polyp on CTC, 911 underwent conﬁrmatory
testing (88.8%; 95% CI 86.2% to 91.4%), and 657 had at least
one matched abnormality (24.1% of the total; 95% CI 21.5%
to 26.6%), giving a per-patient PPV of 72.1%; 95% CI 66.5%
to 77.8% (table 2).
The 116 screenees with abnormal CTC but not undergoing
conﬁrmatory testing included 10 with suspected CRC (1 with
metastases), 25 individuals with 10 mm+ polyps, 40 screenees
with 6–9 mm polyps, 39 with suspected diminutive polyps and
two screenees in whom the CTC polyp diameter was missing.
The reasons for no further testing included death, loss to
follow-up, patient refusal and clinical decisions to not pursue
small polyps in frail screenees.
Additionally, 57 endoscopies were performed without a prior
CTC diagnosis of cancer or polyp. Twelve of these were for sus-
pected benign submucosal abnormalities, three for suspected
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Table 1 Sex and age of screenees investigated by CTC, split by
the individual’s round of screening
Characteristic
Screening round
1 2 3 Total
Men
60–64 years 370 184 6 560
65–69 years 299 284 42 625
70–74 years 123 122 34 279
75+ years 36 5 0 41
Total 828 595 82 1505
Women
60–64 years 307 146 2 455
65–69 years 218 236 36 490
70–74 years 100 115 30 245
75+ years 33 2 1 36
Total 658 499 69 1226
Grand total (M+W) 1486 1094 151 2731
CTC, CT colonography.
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42 endoscopies detected eight additional polyps, ﬁve of which
were adenomas (including a 11 mm adenoma and a 7 mm
adenoma; ﬁgure 1).
Polyp location and morphology was available from CTC for
1062 polyps in 629 screenees. Most polyps (740; 69.7%) were
distal to the splenic ﬂexure; 150 (14.4%) rectal, 447 (42.1%)
sigmoid, 107 (10.1%) descending colon and 36 (3.4%) at the
splenic ﬂexure. The remaining 322 (30.3%) were split as
follows: 119 in the transverse (11.2%), 47 at the hepatic ﬂexure
(4.4%), 87 in the ascending (8.2%) and 69 in the caecum
(6.5%). Polyps were generally either sessile (688; 64.8%) or
pedunculated (328; 30.9%), with relatively few ﬂat lesions (46;
4.3%). Cancer location was available for 110 of the conﬁrmed
124 tumours and showed a similar distal predominance, with
30 (24.2%) rectal, 48 (38.7%) sigmoid, 6 (4.8%) descending
colon, 2 (1.6%) splenic ﬂexure, 7 (5.6%) transverse, 4 (3.2%)
hepatic ﬂexure, 7 (5.6%) ascending colon, 6 (4.8%) caecal and
14 (11.3%) missing data.
Comparison with colonoscopy detection rates
Colonoscopy data were available for 72 817 screenees; 6577
were found to have CRC (9.0%), 14 992 had a 10 mm+ polyp
as the largest colonic abnormality (20.6%), 5773 had 6–9m m
polyps (7.9%) and 16 085 had only diminutive polyps (22.1%).
Advanced neoplasia was detected in 23 830 (32.7%). Table 3
shows colonoscopic and CTC detection rates at various size
thresholds. For screenees with no polyp diameter recorded at
CTC, the endoscopic size was used.
Factors associated with variable CTC abnormality rates,
detection rates and PPV
Outcome after CTC stratiﬁed by sex and screening round is
shown in table 4. CTC abnormality was commoner in men than
in women (632 of 1505 men, 42.0% vs 395 of 1226 women,
32.2%, χ
2=27.0, p<0.001). Detection rates were also greater in
men: 395 of 1505 (26.2%) men had adenoma/CRC conﬁrmed
compared with 197 of 1226 (16.1%) women (χ
2=40.6,
p<0.001). PPV was greater for men, with 436 matched abnor-
malities detected at 564 endoscopies or resections (77.3%) com-
pared with 221 from 347 for women (63.7%, χ
2=19.1,
p<0.001).
Both reported abnormality at CTC, and detection rate dimin-
ished in successive screening rounds, with detection of aden-
omas and cancers falling from 24.4% in round 1 to 19.0% in
round 2, and 13.9% in round 3 (test for equality of propor-
tions, p<0.001), a ﬁnding consistent across all age groups.
Conversely, combined adenoma/CRC detection rate increased
with age (table 5), ranging from 20.6% in the youngest group to
Figure 1 Flowchart of screenees included.
Table 3 Per-screenee detection rates at CTC and colonoscopy by
the largest lesion demonstrated
CTC (n=2731)
Colonoscopy
(n=72 817) p Value*
Colorectal cancer (%) 124† (4.5) 6577 (9.0) <0.0001
10 mm+ polyp (%) 340 (12.4) 14 992 (20.6) <0.0001
10 mm+ adenoma (%) 320 (11.7) 13 571 (18.6) <0.0001
6–9 mm polyp (%) 119 (4.4) 5773 (7.9) <0.0001
6–9 mm adenoma (%) 103 (3.8) 5243 (7.2) <0.0001
≤5 mm polyp (%) 75 (2.7) 16 085 (22.1) <0.0001
≤5 mm adenoma (%) 45 (1.6) 10 870 (14.9) <0.0001
6 mm+ adenoma or CRC (%) 547 (20.0) 25 391 (34.9) <0.0001
10 mm+ adenoma or CRC (%) 444 (16.3) 20 148 (27.7) <0.0001
Advanced neoplasia (%) 504 (18.5) 23 830 (32.7) <0.0001
For CTC, at each size threshold the number of screenees with a matched lesion at
confirmatory testing (endoscopy or surgery) is reported. For colonoscopy, the size
categories are the endoscopic size for polyps and histologic size for adenomas.
Probability value for χ
2 test.
†10 additional screenees had no confirmatory testing but suspected CRC on CT.
CRC, colorectal cancer; CTC, CT colonography.
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exceeded the upper boundary for invitation, had ‘opted-in’).
PPV for CTC was unaffected by screening round or age,
although there was a non-signiﬁcant trend for higher PPV in the
oldest age category when compared with younger screenees
(p=0.08).
Between-centre variation for CTC abnormality, detection
of adenomas and cancers and PPV
Rates of CTC abnormality (ﬁgure 2A), subsequent detection of
adenomas or cancers (ﬁgure 2B), and PPV for CTC (ﬁgure 2C)
were relatively homogeneous across screening centres: only one
centre showed a signiﬁcantly lower detection rate than the
average. Overall, PPV at each centre showed moderate positive
correlation with that centre’s detection rate (Spearman r=0.63).
Because it is possible that different categories of screenee were
referred for CTC at different centres (eg, a greater proportion
of women or young screenees, which would reduce prevalence
of abnormality: table 6) thereby inﬂuencing subsequent
detection rates, we calculated a risk-adjusted detection rate for
each centre by correcting for these covariates with logistic
regression. The risk-adjusted funnel plot is shown in ﬁgure 3
and is similar to the unadjusted data: The low detection centre
retains a lower detection rate when adjusting for the population
being imaged. Supporting this, the regression model estimate
for this centre gave an OR of 0.55 (95% CI 0.20 to 0.96) for
detection of adenomas or cancer, implying that the lower detec-
tion rate was not simply due to case-mix.
Centre factors associated with referral rates, detection
rates and PPV
Although not available from BCSS, a prior survey of the 58
screening centres gathered information on CTC technique, esti-
mated annual centre workload per radiologist (including symp-
tomatic as well as screening practice), and average experience of
the interpreting radiologists at that centre (both symptomatic
and screening cases).
11 Two of the 58 centres provided
Table 5 Number of screenees imaged by CTC, subsequent
referrals for further testing, and ultimate detection for cancer, large
polyp (10 mm+), medium-sized polyp (6–9 mm), any polyp or
cancer, any adenoma or cancer and advanced neoplasia, split by
age and sex
60–64 years 65–69 years 70–74 years 75+ years
Number imaged by CTC
Men 560 625 279 41
Women 455 489 246 36
Total 1015 1114 525 77
Number (%) with suspected polyp or cancer on CTC
Men 227 (40.5) 252 (40.3) 131 (47.0) 22 (53.7)
Women 134 (29.5) 164 (33.5) 77 (31.3) 20 (55.6)
Total 361 (35.6) 416 (37.3) 208 (39.6) 42 (54.5)
Number (%) with proven cancer
Men 25 (4.5) 38 (6.1) 19 (6.8) 7 (17.1)
Women 14 (3.1) 12 (2.5) 8 (3.3) 1 (2.8)
Total 39 (3.8) 50 (4.5) 27 (5.1) 8 (10.4)
Number (%) with matched 10 mm+ polyp
Men 86 (15.4) 91 (14.6) 46 (16.5) 4 (9.8)
Women 45 (9.9) 43 (8.8) 19 (7.7) 6 (16.7)
Total 131 (12.9) 134 (12.0) 65 (12.4) 10 (13.0)
Number (%) with matched 6–9 mm polyp
Men 27 (4.8) 28 (4.5) 14 (5.0) 2 (4.9)
Women 14 (3.1) 20 (4.1) 9 (3.7) 5 (13.9)
Total 41 (4.0) 48 (4.3) 23 (4.4) 7 (9.1)
Number (%) with any matched polyp or cancer
Men 158 (28.2) 180 (28.8) 83 (29.7) 15 (36.6)
Women 78 (17.1) 89 (18.2) 41 (16.7) 13 (36.1)
Total 236 (23.3) 269 (24.1) 124 (23.6) 28 (36.4)
Number (%) with any matched adenoma or cancer
Men 141 (25.2) 159 (25.4) 80 (28.7) 15 (36.6)
Women 68 (14.9) 78 (16.0) 37 (15.0) 14 (38.9)
Total 209 (20.6) 237 (21.3) 117 (22.3) 29 (37.7)
Number (%) with advanced neoplasia
Men 115 (20.5) 145 (23.2) 69 (24.7) 11 (26.8)
Women 58 (12.7) 63 (12.9) 32 (13.0) 11 (30.6)
Total 173 (17.0) 208 (18.7) 101 (19.2) 22 (28.6)
Percentages use the total number of screenees imaged by CTC of that sex and age
category as the denominator.
Age, sex and individual’s screening round were highly significant predictors of CTC
detection rates in both univariate and multivariate analysis (table 6).
CTC, CT colonography.
Table 4 Total screenees imaged by CTC, subsequent
abnormalities found at CTC, and ultimate detection rates for cancer,
large polyp (10 mm+), medium-sized polyp (6–9 mm), any polyp or
cancer, any adenoma or cancer and advanced neoplasia, each split
by sex and individual’s screening round
First round Second round Third round Total
Total imaged by CTC
Men 828 595 82 1505
Women 658 499 69 1226
Total 1486 1094 151 2731
Number (%) with polyp or cancer suspected on CTC
Men 373 (45.0) 235 (39.5) 24 (29.3) 632 (42.0)
Women 231 (35.1) 148 (29.7) 16 (23.2) 395 (32.2)
Total 604 (40.6) 383 (35.0) 40 (26.5) 1027 (37.6)
Number (%) with proven cancer
Men 55 (6.6) 32 (5.4) 2 (2.4) 89 (5.9)
Women 21 (3.2) 14 (2.8) 0 (0.0) 35 (2.9)
Total 76 (5.1) 46 (4.2) 2 (1.3) 124 (4.5)
Number (%) with matched 10 mm+ polyp
Men 142 (17.1) 79 (13.3) 6 (7.3) 227 (15.1)
Women 78 (11.9) 31 (6.2) 4 (5.8) 113 (9.2)
Total 220 (14.8) 110 (10.1) 10 (6.6) 340 (12.4)
Number (%) with matched 6–9 mm polyp
Men 36 (4.3) 31 (5.2) 4 (4.9) 71 (4.7)
Women 24 (3.6) 21 (4.2) 3 (4.3) 48 (3.9)
Total 60 (4.0) 52 (4.8) 7 (4.6) 119 (4.4)
Number (%) with any matched polyp or cancer
Men 263 (31.8) 159 (26.7) 14 (17.1) 436 (29.0)
Women 142 (21.6) 72 (14.4) 7 (10.1) 221 (18.0)
Total 405 (27.3) 231 (21.1) 21 (13.9) 657 (24.1)
Number (%) with any matched adenoma or cancer
Men 237 (28.6) 144 (24.2) 14 (17.1) 395 (26.2)
Women 126 (19.1) 64 (12.8) 7 (10.1) 197 (16.1)
Total 363 (24.4) 208 (19.0) 21 (13.9) 592 (21.7)
Number (%) with advanced neoplasia
Men 209 (25.2) 119 (20.0) 12 (14.6) 340 (22.6)
Women 106 (16.1) 50 (10.0) 8 (11.6) 164 (13.4)
Total 315 (21.2) 169 (15.4) 20 (13.2) 504 (18.5)
To calculate percentages for each cell of the table, the total number of screenees of
the corresponding gender and screening round was used as the denominator.
CTC, CT colonography.
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data presented above.
Average radiologist experience strongly inﬂuenced the propor-
tion of CTC reported as abnormal, combined adenoma/CRC
detection rate, and PPV: all increased in line with experience
(table 7). Similarly, centres performing more CTC (including
symptomatic practice) reported more abnormalities, detected
more adenomas/CRC and had a higher PPV than lower-volume
centres; 3D interpretation (either a primary 3D strategy or equal
use of 3D and 2D) was also beneﬁcial, with signiﬁcantly higher
rates of CTC abnormality and adenoma/CRC detection, at
equivalent PPV when compared with centres using a 2D
approach. Bowel preparation had a variable effect on diagnostic
performance, with centres combining bowel purgation with
faecal tagging detecting slightly more adenomas and cancers
than centres using either purgation or tagging alone although
the difference was not statistically signiﬁcant. PPV was signiﬁ-
cantly lower for the combined preparation (table 7).
The logistic regression model used screenee age, gender and
screening with additional covariates of average radiologist
experience (<300 total CTC experience, 300–999, 1000+),
centre workload (<175 CTC/radiologist/annum vs 175+),
bowel preparation (cleansing and tagging combined vs either
alone) and reading strategy (2D vs 3D). All except the method
of bowel preparation remained signiﬁcant in a random effects
model (table 8). The interaction between experience and
reading strategy was also modelled, but was not signiﬁcant.
Stage of cancers detected
Dukes’ stage was available for 116 of the 124 patients with his-
tologically proven cancer. Seven of the eight cancers with a
missing Dukes’ stage were T1 lesions but had no N stage, pos-
sibly due to local resection (precluding a pathological N stage).
Stage compared with distribution in the whole BCSP (reported
Figure 2 (A) Unadjusted CT colonography (CTC) abnormality rate, (B) unadjusted detection rates of matched adenomas and cancer and
(C) positive predictive value (PPV) for CTC by screening centre. The dashed lines correspond to upper and lower 95% control limits, and the dotted
lines represent 99.9% limits. Two centres had a high abnormality rate at CTC but both lay within the control limits when considering proven
adenomas and cancers (arrows in (A) and (B)). One of these centres had a PPV that was at the lower control limit (arrow in (C)). A different centre
had a borderline CTC abnormality rate and low adenoma/cancer detection (arrowheads in (A) and (B)).
Figure 3 Adjusted detection rate at CT colonography by screening
centre with 95% (dashed) and 99.9% (dotted) control limits. The
low-detection outlier shown in ﬁgure 2B is unchanged (arrowhead).
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17) is shown in table 9. Overall stage distribution
was similar, suggesting that CTC-diagnosed neoplasms are
equally likely to be found at an early, curable stage.
DISCUSSION
The success of the BCSP depends on thorough colonic investiga-
tion after positive gFOBT. Colonoscopy is the reference stand-
ard and has been instituted nationally with excellent safety and
quality.
18 Nevertheless, around 2% of screenees cannot undergo
colonoscopy
7 (rising to 9% at some centres
19), so CTC is
recommended.
6 Meta-analysis suggests CTC has equivalent sen-
sitivity to colonoscopy for cancer,
20 and around 90% sensitivity
for adenomas of 1 cm or greater.
21 22 Detection rates of
advanced neoplasia at screening CTC and colonoscopy were
equal in two large cohort studies,
10 23 and randomised data
suggest that CTC is not signiﬁcantly different from colonoscopy
for detection of cancers and large polyps in symptomatic
patients.
24 CTC has also been evaluated speciﬁcally in
gFOBt-positive screenees, achieving a sensitivity of 95% for
cancer and 1 cm+ polyps combined
25 and 86.5% for 6 mm+
advanced adenomas.
26 These data suggest CTC can substitute
for colonoscopy when the latter is undesirable.
We found substantially lower detection rates for CTC than
for colonoscopy. Cancer detection rates were 4.5% for BCSP
screenees undergoing CTC and 9.0% for those having
colonoscopy. Similarly, whereas 20.6% of screenees undergoing
colonoscopy had a 10 mm+ polyp as the largest colonic abnor-
mality, only 12.4% of screenees undergoing CTC had a large
polyp conﬁrmed. Detection of advanced neoplasia was 32.7%
and 18.5%, respectively.
There are several possible explanations for this. Most obvi-
ously, populations undergoing CTC or colonoscopy are different
since CTC is performed when colonoscopy is contraindicated.
Because referral criteria for CTC are subject to interpretation,
selection bias might reduce the prevalence of neoplasia in those
having CTC. For example, CTC might be used preferentially in
those deemed low-risk because of recent normal colonoscopy or
a strong alternative explanation for a positive gFOBt. Atlhough
we have no direct evidence of this, such biases are possible.
Additionally, 11% of screenees with pathology suspected at
CTC did not undergo further testing, thereby reducing detec-
tion rates of conﬁrmed neoplasia. Differences between polyp
diameters at CTC and colonoscopy may also alter detection
rates at various size thresholds, since neither technique measures
diameter perfectly.
27 We found there was a tendency for polyp
diameters to cluster at 5 mm intervals (data not shown), imply-
ing ‘rounding’ to the nearest 5 mm, which might skew detection
rates based on size thresholds. Furthermore, many subjects
investigated with CTC take anticoagulants such as warfarin or
antiplatelets, including clopidogrel. Whether these affect gFOBt
is controversial,
28–30 but clopidogrel, in particular, is implicated
as a cause of false-positive gFOBt.
31 Women are also relatively
over-represented at CTC when compared with colonoscopy
(1.2: 1 M:F ratio in our study vs 1.5 :1 in the report of the ﬁrst
million individuals screened).
7 Since women also have lower
prevalence of neoplasia, this will diminish overall CTC detec-
tion rates.
However, lower detection rates may be because CTC, as cur-
rently practiced in the BCSP , has unexpectedly low sensitivity.
Interval cancer rates may help determine if CTC misses signiﬁ-
cantly more cancers than colonoscopy; these data are currently
being collected. Although the available literature suggests CTC
has similar sensitivity to colonoscopy for cancers and large
polyps, these data may not generalise to the BCSP . BCSP endos-
copists have undergone extensive quality assurance. Conversely,
CTC in the BCSP is relatively novel and has not been subject to
similar stipulations. Multicentre studies of CTC have used
Table 7 Institutional factors associated with varying CTC abnormality rates, detection of adenomas and cancers, and PPV
Variable Abnormality rate at CTC (%)
Detection of adenomas
and cancers (%) PPV (%)
Average radiologist experience
<300 cases 154/474 (32.5) 82/474 (17.3) 82/134 (61.2)
300–999 cases 384/1006 (38.2) 205/1006 (20.4) 205/340 (60.3)
1000+ cases 450/1119 (40.2)* 282/1119 (25.2)* 382/400 (70.5)*
Average radiologist workload
<175 cases/radiologist/annum 291/851 (34.2) 145/851 (17.0) 145/247 (58.7)
≥175 cases/radiologist/annum 697/1748 (39.9)† 424/1748 (24.3)† 424/627 (67.6)†
Interpretation strategy
Primary two-dimensional interpretation 316/973 (32.5) 183/973 (18.8) 183/286 (64.0)
two-dimensional interpretation 711/1758 (40.4)† 409/1758 (23.3)† 409/625 (57.5)
Bowel preparation
Either purgation or tagging 493/1456 (33.9) 301/1456 (20.7) 301/439 (68.6)†
Both purgation and tagging combined 495/1143 (43.3)† 268/1143 (23.4) 268/435 (61.6)
*χ
2 Test for trend in proportions, p<0.05.
†χ
2 Test, p<0.05 when compared with the other category of the same variable.
CTC, CT colonography; PPV, positive predictive value
Table 6 Screenee factors associated with detection of adenomas
or CRC, derived by logistic regression and expressed as ORs
Screenee factor
Univariate OR
(95% CI)
Multivariate OR
(95% CI) p Value*
Men versus women 1.83 (1.52 to 2.22) 1.84 (1.52 to 2.23) <0.001
Screened for second
time versus first time
0.73 (0.60 to 0.89) 0.72 (0.59 to 0.87) <0.001
Screened for third
time versus first time
0.49 (0.30 to 0.76) 0.44 (0.26 to 0.69) <0.001
Age (per year
increase)
1.03 (1.01 to 1.05) 1.04 (1.02 to 1.06) <0.001
*Probability value for the Wald z-score for both univariate and multivariate analysis.
CRC, Colorectal cancer;
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32 highly
experienced readers
33 or motivated subspecialists with add-
itional training.
82 4Radiologists in the BCSP , while almost uni-
versally trained in basic CTC interpretation and, frequently,
subspecialists in gastrointestinal imaging,
11 may not have
attained a similar degree of experience or training. Like colonos-
copy prior to the BCSP ,
34 it is known that radiologist perform-
ance may be highly variable, with sensitivity for 1cm+ lesions
ranging between 67 and 100% in one multicentre study.
32
Although a recent analysis of detection rates from a single US
centre showed relatively little variation in neoplasia detection
between radiologists,
35 replicating this across multiple centres
may be more difﬁcult.
A quality assurance programme for CTC, as for colonoscopy,
should help minimise differences in diagnostic accuracy. Despite
CTC having lower detection rates than colonoscopy, it remains
the preferred radiological investigation in the BCSP when colon-
oscopy is not desirable.
6 Reinforcing this, cancer detection rates
for barium enema in the BCSP were even lower than for CTC
(3.6%, full data not shown). It is important to note that this is a
difﬁcult population to image. These screenees are frail and have
already been judged unsuitable for colonoscopy. Therefore,
achieving optimal CTC image quality and diagnostic perform-
ance is challenging. Even if the lower detection rates we describe
are partly due to missed lesions at CTC, there is no guarantee
that an alternative test (including colonoscopy) would fare
better—these individuals will likely be difﬁcult to endoscope
safely, and neoplasia detection rates might be no different. We
would therefore caution against interpreting our data to argue
for or against CTC in frailer screenees, since the outcomes of
the alternative (colonoscopy) are unknown.
We found that centres with increasing average radiologist
experience and higher CTC workload had higher detection
rates, supporting the hypothesis that CTC requires considerable
experience to maximise diagnostic performance. Our data raise
the possibility that less experienced BCSP radiologists are
missing lesions, although this has not been directly proven
because data are unrandomised. An alternative explanation is
further selection bias. Less experienced radiologists are likely to
work at centres whose CTC service is nascent. The presumed
selection biases contributing to lower CTC detection rates (vs
colonoscopy) nationally might be particularly severe at these
centres because referrers have less conﬁdence in CTC. Notably,
average radiologist experience did not become signiﬁcant in our
study until the number of cases interpreted exceeded 1000, sub-
stantially greater than previous training recommendations.
36
Adenoma detection rates by endoscopists continue to increase
over several hundred examinations.
37 A higher total CTC case-
load per radiologist per annum was also associated with superior
detection. Interestingly, it did not appear that radiologists with
higher detection rates were simply over-reporting equivocal
ﬁndings at CTC. In fact, the converse was true: radiologist
experience was associated with signiﬁcantly higher PPV , suggest-
ing that not only were more experienced radiologists more
likely to report an abnormality at CTC, they were also more
likely to be correct when doing so.
Interpretation using 3D images (ie, ‘virtual colonoscopy’)
was associated with higher detection rates. While this may be
because 3D visualisation helps detect polyps, it may also be a
proxy for other measures that inﬂuence diagnostic perform-
ance; for example, a high-quality workstation, training, or
sufﬁcient reporting time to incorporate 3D search. Existing
literature is unclear if 3D interpretation is superior
38 or
not.
39 Nevertheless, whether directly associated or not, we
found a primary 2D strategy was associated with lower diag-
nosis and detection rates. The precise method used for bowel
preparation did not seem to be a signiﬁcant factor after
adjusting for age, sex and the individual’sp r i o rs c r e e n i n g
history.
PPV in our study was lower at 72.1% than prior studies of
both FOBt-positives (87%
40) and average-risk individuals (92–
96%
41–43), although we found PPV for CRC and 1 cm+ polyps
was good (87%). The difference may partly be due to different
patient populations—our study describes screenees with relative
contraindications to colonoscopy, whereas, existing literature
does not preselect in this manner. As noted above, these indivi-
duals are difﬁcult to image, and therefore, equivocal ﬁndings
may have been reported as positive, lowering PPV .
Table 8 Screenee and institutional factors associated with detection rates following CTC, derived via a multilevel logistic regression model and
expressed as ORs
Variable Crude OR p Value* Random effects model OR p Value*
Screenee factors Men (vs women) 1.86 (1.56 to 2.23) <0.001 1.83 (1.50 to 2.23) <0.001
Screened for second time (vs first time) 0.73 (0.60 to 0.87) <0.001 0.75 (0.61 to 0.93) <0.001
Screened for third time (vs first time) 0.46 (0.29 to 0.69) <0.001 0.43 (0.26 to 0.70) <0.001
Age (per year increase) 1.04 (1.02 to 1.06) <0.001 1.04 (1.02 to 1.06) <0.001
Institutional factors Three-dimensional review of images (vs primary two-dimensional) 1.31 (1.07 to 1.60) 0.010 1.38 (1.02 to 1.95) 0.023
Experience of radiologist (vs <300 cases)
High (1000+ cases) 1.49 (1.16 to 1.94) 0.020 1.44 (1.02 to 2.04) 0.038
Medium (300–999 cases) 1.18 (0.90 to 1.54) 0.23 1.22 (0.87 to 1.72) 0.26
High workload (>175 cases per radiologist per annum, vs less than this) 1.52 (1.22 to 1.89) 0.017 1.41 (1.02 to 1.93) 0.032
Use of purgation combined with tagging (vs either alone) 1.14 (0.95 to 1.38) 0.16 1.12 (0.85 to 1.48) 0.40
*Probablility value for the Wald z-score. Italic values are significant at the 5% level.
CTC, CT colonography.
Table 9 Stage distribution of cancers confirmed by endoscopy
following CTC alone compared with cancer stage across the whole
BCSP
Stage CTC total* CTC percentage BCSP total† BCSP percentage
Dukes A 37 29.8 614 28.9
Dukes B 38 30.6 517 24.4
Dukes C 34 27.4 497 23.4
Dukes D 7 5.6 121 5.7
Missing 8 6.5 374 17.6
*10 further cancers were suspected radiologically but not confirmed histologically.
†This total will include a small number of cancers diagnosed by CTC, albeit likely
fewer than 15.
BCSP, Bowel Cancer Screening Programme; CTC, CT colonography.
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the accuracy of which is unknown currently. Of note, analysis of
other large databases (including the National Bowel Cancer
Audit Project, NBOCAP) suggested inadequate performance
that was ultimately due to upload of inaccurate data.
44 Our own
local audit at two of the largest centres in terms of CTC volume
suggests the database accuracy exceeds 90% (data not shown).
However, this may not apply to all centres. The planned intro-
duction of a minimum dataset for CTC reporting in the BCSP
should improve accuracy of centrally held data. A further limita-
tion is that centre-level data regarding speciﬁc CTC factors (eg,
average radiologist experience and reading strategy) were
inferred from a separate survey.
11
In summary, screenees undergoing CTC as the primary inves-
tigation following positive gFOBt in the English BCSP have a
18.5% rate of advanced neoplasia, compared with 32.7% for
colonoscopy. The reasons for this difference are likely to be
multifactorial, but selection bias and/or suboptimal diagnostic
performance of CTC are possible. Radiologist inexperience was
associated with lower detection rates and PPV . A primary 2D
reading strategy was also associated with lower detection rates.
A rigorous quality assurance process for radiology in the BCSP
is being instituted and will devise methods to ensure high-
quality imaging is available universally.
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